| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| "Crises" in medical malpractice insurance: Evidence of excessive price-cutting in the preceding soft market |
0 |
0 |
0 |
39 |
0 |
0 |
1 |
188 |
| A general model of the impact of absenteeism on employers and employees |
0 |
0 |
1 |
142 |
0 |
0 |
3 |
691 |
| A measure of malpractice: Medical injury, malpractice litigation and patient compensation, by Paul C. Weiler et al. Cambridge, MA: Harvard University Press, 1993, 178 pp., $29.95 cloth |
0 |
0 |
0 |
17 |
0 |
0 |
1 |
61 |
| Alternative Liability Regimes for Medical Injuries |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
16 |
| At what price? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
| Comments on "The Assault on Managed Care: Vicarious Liability, ERISA Preemption, and Class Actions." |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
294 |
| Contingent Fees for Personal Injury Litigation |
0 |
0 |
0 |
82 |
0 |
0 |
0 |
865 |
| Cross-national price differences for pharmaceuticals: how large, and why? |
0 |
1 |
2 |
320 |
0 |
1 |
4 |
729 |
| Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues |
0 |
1 |
5 |
14 |
0 |
2 |
7 |
43 |
| Does Regulation Drive out Competition in Pharmaceutical Markets? |
0 |
0 |
0 |
27 |
1 |
2 |
4 |
1,151 |
| Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion |
1 |
1 |
4 |
80 |
1 |
2 |
7 |
221 |
| Health Care Reform |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
25 |
| Health Insurance and the Growth in Pharmaceutical Expenditures |
0 |
0 |
0 |
13 |
0 |
0 |
1 |
56 |
| Holdouts, Externalities, and the Single Owner: One More Salute to Ronald Coase: Comment |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
246 |
| Hospital `profits': The effects of reimbursement policies |
0 |
0 |
1 |
38 |
0 |
0 |
1 |
139 |
| Liability and liability insurance for medical malpractice |
0 |
0 |
1 |
58 |
0 |
1 |
4 |
180 |
| Liability for Medical Malpractice |
0 |
0 |
2 |
198 |
1 |
1 |
5 |
674 |
| Medical negligence and the NHS: an economic analysis |
0 |
0 |
1 |
1 |
0 |
0 |
1 |
161 |
| Mergers and acquisitions in the pharmaceutical and biotech industries |
0 |
1 |
1 |
326 |
1 |
3 |
15 |
1,061 |
| Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement |
0 |
2 |
2 |
6 |
0 |
2 |
7 |
50 |
| Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive? |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
34 |
| Price Cutting in Liability Insurance Markets |
1 |
1 |
1 |
110 |
1 |
1 |
2 |
471 |
| Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU |
0 |
1 |
4 |
151 |
2 |
4 |
13 |
400 |
| Price, Financial Quality, and Capital Flows in Insurance Markets |
0 |
0 |
3 |
118 |
1 |
1 |
7 |
390 |
| Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances |
0 |
0 |
0 |
120 |
3 |
4 |
12 |
581 |
| Rate Regulation, Safety Incentives, and Loss Growth in Workers' Compensation Insurance |
0 |
0 |
0 |
77 |
0 |
0 |
0 |
650 |
| Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand |
0 |
0 |
0 |
76 |
1 |
2 |
3 |
447 |
| Regulation and its reform, by Stephen Breyer. Cambridge, MA: Harvard University Press, 1982, 472 pp. Price: $25.00 |
0 |
0 |
2 |
86 |
0 |
3 |
7 |
303 |
| Regulatory policy and practices: Regulating better and regulating less, by Fred Thomson and L.R. Jones. New York: Praeger Publishers, 1982, 253 pp. Price: $29.95 |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
21 |
| Risk by choice: Regulating health and safety in the workplace, by W. Kip Viscusi. Cambridge, MA: Harvard University Press, 1983, 200 pp. Price: $18.50 |
0 |
0 |
0 |
6 |
0 |
0 |
3 |
48 |
| Separation of the redistributive and allocative functions of government: A public choice perspective |
0 |
0 |
0 |
68 |
0 |
0 |
0 |
463 |
| The Economic Implications of Public Disability Insurance in the United States |
0 |
0 |
0 |
46 |
0 |
0 |
0 |
205 |
| The Effects of Malpractice Litigation on Physicians' Fees and Incomes |
0 |
0 |
0 |
53 |
0 |
0 |
0 |
183 |
| The Frequency and Severity of Medical Malpractice Claims |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
596 |
| The Political Economy of Workers' Compensation: Lessons for Product Liability |
1 |
1 |
2 |
10 |
1 |
1 |
2 |
65 |
| The Swedish patient compensation system: Myths and realities |
0 |
0 |
1 |
94 |
1 |
1 |
5 |
225 |
| The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s |
0 |
0 |
0 |
84 |
0 |
1 |
2 |
349 |
| Tort Liability: A Minefield for Managed Care? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
232 |
| Tort Reform: The Case of Medical Malpractice |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
455 |
| Vaccine Supply: Effects of Regulation and Competition |
0 |
0 |
0 |
25 |
1 |
1 |
3 |
191 |
| Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context |
0 |
0 |
1 |
21 |
0 |
1 |
7 |
137 |
| Welfare effects of supplementary insurance: a comment |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
73 |
| Worker's Compensation Rate Regulation: How Price Controls Increase Costs |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
428 |
| Total Journal Articles |
3 |
9 |
34 |
2,564 |
15 |
34 |
129 |
13,799 |
LogEc is hosted by the
Örebro University School of Business.